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Purpose: Elevations of  plasmin have been implicated in the pathogenesis of  abdominal 
aortic aneurysms (AAA) because of  its abil ity to digest extracellular matrix proteins. 
Plasminogen activators regulate the conversion of  plasminogen to plasmin. Tissue-type 
plasminogen activator (tPA) is more important in modulat ion of  fibrinolysis, and uroki- 
nase-type plasminogen activator (uPA) is predominant in tissue remodeling. The purpose 
of  this study was to determine the levels of  plasminogen activators in diseased aorta 
because they may be responsible for the increased plasmin levels previously described in 
AAA. 
Methods: Levels o f tPA  and u_PA in AAA, occlusive, and normal (organ donor) aorta were 
studied in tissue explant supernatants. Supernatant tPA and uPA levels were measured 
with an enzyme-linked immunosorbent assay. Northern analysis was used to quantitate 
uP_& messenger RNA (mRNA) levels in aortic tissue. 
Results: Levels of  tPA in the supernatants were similar in occlusive (20 - 4 ng /ml )  and 
AAA (23 -+ 8) aorta, but  threefold higher than in normal aorta (7 - 5; p < 0.005 for 
normal vs occlusive and p < 0.001 for normal vs AAA). In contrast, uPA supernatant 
levels were differentially expressed, with the highest level existing in AAA (9.7 + 2.7 
ng /ml ) ,  followed by occlusive (4.9 - 3.5), and the lowest levels in normal aorta (1.2 -+ 
0.7; p < 0.05 for normal vs occlusive, p < 0.001 for normal vs AAA, and p < 0.005 for 
occlusive vs AAA). Inhibit ion of  protein or RNA synthesis by addit ion of  cyclohexamide 
or actinomycin D, respectively, revealed no significant difference between treated and 
control supernatants, suggesting that the increases were caused by protein release rather 
than active synthesis. Levels of  uPA mRNA followed the same trend as the supernatant 
uPA levels (AAA 1.07 -+ 0.54, occlusive 0.54 -+ 0.08, and normal aorta 0.01 -+ 0.01). 
Conclusions: Levels o f tPA  were similar in aneurysmal nd occlusive aorta, but exhibited a
threefold increase over normal aorta, suggesting that the elevations of  tPA are associated 
with the arteriosclerosis present in both aneurysmal nd occlusive disease. Differences in 
uPA levels were significant between all three groups, with the highest levels in AAA and 
the lowest levels in normal specimens. Northern analysis of  uPA mRNA followed the 
same trend, suggesting that the increase in u_PA may be regulated at the level of  
transcription. As uPA plays an important role in tissue remodeling, our findings may also 
reflect he relative tissue repair activities in these three types of  specimens and may explain 
the previously reported increased levels of  plasmin seen in AAA. (J Vasc Surg 1997; 
25:157-64.) 
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Tissue-type plasminogen activator (tPA) and 
urokinase-type lasminogen activator (uPA) convert 
the proenzyme plasminogen into its active form, 
plasmin. Plasmin is important in tissue remodeling 
and in fibrinolysis. Jean-Claude t al.1 described ele- 
vated levels of plasmin in abdominal aortic aneu- 
rysms (AAA) as compared with controls, suggesting 
that plasmin may be important in the pathogenesis of
aneurysm formation. Plasmin plays a key role in the 
degradation of extraccllular matrix (ECM) by di- 
rectly digesting matrix proteins, as well as by activat- 
ing the proteolytic matrix metalloproteinases 
(MMPs).2 
Proteolytic activity in the aortic wall varies with 
disease state. Vine and Powell 3 demonstrated anin- 
creased gelatinase activity in homogenates from an- 
eurysmal and occlusive atherosclerotic aorta. In addi- 
tion, collagenase and stromelysin were detected in 
aneurysmal orta, but rarely in occlusive specimens, 
and never in normal samples.-Plasmin, a nonspeciflc 
protease, activates these enzymes as well as directly 
degrading many ECM proteins. Both tPA and uPA 
arc present in the aneurysmal wall, and both of these 
enzymes convert plasminogen to plasmin. Reilly et 
al.4 studied the level of plasminogen activators in 
protein extracts derived from aneurysmal, occlusive, 
and normal aorta. Immunoassay demonstrated dif- 
ferential expression of tPA, with the highest level in 
AAA, followed by normal aorta, and the lowest level 
in occlusive specimens. They were unable to quanti- 
tate uPA antigen by immunoassay in any of the 
specimens. A more sensitive method--fibrin autog- 
raphy--dcmonstrated activity attributable to both 
tPA and uPA, with the largest amount offibrinolysis 
occurring because of free tPA. Expression of uPA 
and tPA mRNA was comparable in aneurysmal nd 
occlusive specimens. 
Increased proteolytic activity has been demon- 
strated in the wall of AAA, and this increase may at 
least partially be explained by increased plasmin lev- 
els. Regulation of plasminogen activation is an im- 
portant area of investigation because of plasmin's 
involvement in both fibrinolysis and tissue remodel- 
ing. To date, quantitation of uPA protein levels has 
not been reported in diseased aorta. The purpose of 
this study was to compare levels of tPA and uPA in 
aneurysmal, occlusive, and normal aorta. 
METHODS 
The following studies were performed with the 
approval of the Institutional Review Board of North- 
western University, and all patients gave informed 
consent. Infrarenal aorta (aneurysmal nd occlusive) 
was obtained at the time of bypass grafting. Normal 
thoracic and abdominal aorta was procured from 
organ donors through the Regional Organ Bank of 
Illinois. 
Tissue explant supernatants. In the operating 
room, specimens were placed on ice in holding me- 
dia (Dulbecco's Modified Eagle's Medium, Ham's 
F-12, 16% fetal bovine serum, penicillin/streptomy- 
cin, and amphotericin B) and processed within 1 to 2 
hours. Using sterile technique, the tissue was washed 
with phosphate buffered saline solution (PBS) to 
remove residual thrombus, minced into 1 × 1 mm 
squares, weighed, and placed into 4 ml Roswell Park 
Memorial Institute (RPMI) media with penicillin/ 
streptomycin per 1 g of tissue. The specimens were 
incubated at 37 ° C with 5% CO 2 for 48 hours. The 
supematant was removed, centrifuged, aliquoted, and 
stored at -80°C until assayed. Time course experi- 
ments were performed by placing similar amounts of 
tissue from the same patient into separate flasks at 
37 ° C and collecting the supernatants at0, 4, 8, 24, 
48, and 72 hours. Protein and RNA synthesis were 
inhibited respectively by cyclohexamide (25 txg/ml) 
and actinomycin D (5 Ixg/ml). The inhibitors were 
dissolved in alcohol and added to the RPMI media at 
time zero and were in contact with the tissue for 72 
hours. Control flasks contained tissue from the same 
patient placed in the RPMI media-alcohol mixture 
without he respective inhibitors. 
Quantitation of tPA and uPA. Total tPA and 
uPA antigen was quantitated using TintElize tPA 
and TintElize uPA (Biopool International, Ventura, 
Calif.), respectively. These enzyme-linked immu- 
nosorbent assays recognize all forms oftPA and uPA. 
Manufacturer's instructions for nonplasma samples 
were followed, and interassay variability was pprox- 
imately 5%. 
Northern blot analysis. Total RNA was ex- 
tracted from snap-frozen tissue using the method of 
Chomczynski and Sacchi. 5 RNA was quantified by 
measuring absorbance at260 nm, and approximately 
10 ~g of cellular RNA was size fractionated on a 1% 
formaldehyde agarose gel. The samples were electro- 
phoresed with ethidium bromide to verify the integ- 
rity of the ribosomal RNA. The RNA was transferred 
to a nylon membrane and hybridized overnight. A 
Prime-It II Kit (Stratagene, LaJolla, Calif.) was used 
with [32p] deoxyadenosine-triphosphate to synthe- 
size radiolabeled probes. A 1.1 kb uPA probe was 
donated by Abbott Laboratories (Abbott Park, Ill.) 
and a 1.0 kb glyceraldehyde-3-phosphate dehydro- 
genase (GAPDH) probe was kindly provided by Dr. 
Kathy Green (Northwestern University, Chicago). 
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The signal was quantitated using a Fuji Bio-imager 
BAS 2000 (Tokyo, Japan) and reported as pulses 
minus background ivided by the area. Tissue cul- 
ture RNA from microvascular endothelial cells, 
kindly provided by Dr. Tom Lawley (Centers for 
Disease Control, Atlanta) and RKO, a colon cancer 
cell line, generously donated by Dr. Douglas Boyd 
(M.D. Anderson Cancer Center, Houston) ,  were 
used as positive controls. The 2.5 kb uPA band was 
divided by the GAPDH signal to normalize for 
differences in RNA loading. Before the second 
hybridization, the membrane was stripped in boil- 
ing 0.1 × SSC, 0.1% SDS to remove the bound 
probe. 
Statistics. Analysis of  variance (ANOVA) and 
unpaired and paired Student's t tests were per- 
formed, and results for these tests were reported as 
significant at the p < 0.05 level. Results are reported 
as the average + standard eviation. 
RESULTS 
Tissue explant supernatants,  tPA and uPA 
were assayed in 48 hour supernatants of 19 patients 
(7 aneurysms, 4 occlusive, and 8 normal). The aver- 
age patient age was 66 + 10 years for aneurysmal 
aorta, 50 + 13 years for occhisive aorta, and48 + 13 
years for normal aorta. 
Aneurysmal aorta had an average of 23 + 8 ng 
tPA/ml  of supernatant, occlusive specimens had 
20 + 4, and normal aorta averaged 7 + 5. ANOVA 
among all three groups revealed p = 0.0003. Fisch- 
er's least square differences was used as an adjunct 
test and revealed a p < 0.001 for normal versus 
aneurysmal orta and a p < 0.005 for normal versus 
occlusive aorta. There was no significant difference 
between aneurysmal nd occlusive aortic tPA levels. 
uPA (ng/ml)  in the supernatants averaged 9.7 -+ 
2.7 in aneurysmal orta, 4.9 + 3.5 in occlusive aorta, 
and 1.2 + 0.7 in normal aorta. ANOVA among all 
three groups revealed a p < 0.0001. Fischer's least 
square differences revealed a p < 0.0001 for aneu- 
rysm versus normal aorta, a p < 0.005 for aneurysm 
versus occlusive aorta, and p = 0.02 for normal 
versus occlusive aorta. Supernatant uPA was differen- 
tially expressed in all three aortic types, with aneurys- 
mal specimens exhibiting the highest level, followed 
by occlusive and normal specimens. In contrast, 
there was no significant difference in supernatant tPA 
levels in aneurysmal and occlusive aorta, but the 
diseased specimens exhibited a threefold higher level 
than normal aorta. 
Time point experiments were conducted to see 
how tPA and uPA levels changed over time in the 
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Fig. 1. Supernatant time course xperiments. A, Levels of 
tPA in aneurysmal supernatants increased over time, while 
levels of tPA in normal specimens initially increased and 
slightly declined after 8 hours. B, Levels of uPA in both 
normal and aneurysmal supernatants increased over time, 
with aneurysmal specimens exhibiting a steady increase 
throughout entire time period, and normal specimens in- 
creasing initially and then remaining relatively constant 
after 8 hours. 
supernatants. A total of  7 specimens, 3 aneurysms 
and 4 normals, were assayed and the average patient 
age was 68 +_ 2 years for aneurysmal orta and 44 + 
18 years for normal aorta. Levels oftPA (Fig. 1, A) in 
both normal and aneurysmal supernatants rapidly 
increased until the 8 hour point. After 8 hours, tPA 
in the aneurysms continued to slowly rise while tPA 
levels in the normals lightly decreased. 
Levels of  uPA (Fig. 1, B) in both normal and 
aneurysmal supernatants continued to rise over the 
entire 72 hour period. Aneurysms exhibited a steady 
increase in uPA while normal specimens remained 
relatively constant after 8 hours. 
To determine whether the increase over time was 
a result of  active synthesis or of cell death with release 
of the plasminogen activators, cyclohexamide, or ac- 
tinomycin D was added to the media to inhibit pro- 
tein or RNA synthesis, respectively. Inhibitor studies 
were performed on 7 specimens, which included 4 
aneurysms and 3 normal aortas. There was no signif- 
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Fig. 2. Northern blot analysis ofuPA. 2.5 kb uPA mRNA band migrates between 28S and 18S 
ribosomal bands (arrows). Constitutively produced GAPDH was used to correct for RNA 
loading. E and H on either end represent endothelial cell and colon cancer tissue culture RNA 
used as positive controls. N denotes normal, O, occlusive, and A, aneurysmal aorta. Notice 
absence ofuPA bands on lanes containing RNA from normal tissues but strong GAPDH signal, 
suggesting that amount of uPA in these specimens was below level of detection for Northern 
analysis. 
icant difference in tPA or uPA levels using a paired 
Student's t test in control, cyclohexamide, or actino- 
mycin D supernatants (tPA: control, 14 -+ 9; cyclo- 
hexamide, 11 _+ 8; and actinomycin D, 11 +_ 8; uPA: 
control, 4.2 _+ 3.1; cyclohexamide, 4.2 -+ 3.2; and 
actinomycin D, 4.3 +_ 3.1). These results suggest 
that tPA and uPA are released into the supernatants 
and are not actively synthesized. Previous studies 
measuring plasminogen activator inhibitor type 1 
(PAId)  in the inhibitor supernatants revealed a de- 
crease of  PAI-1 to 33% of control levels, indicating 
that active synthesis had occurred for PAI-1 and 
demonstrating that both protein and RNA synthesis 
hadbeen inhibited by the addition of cyclohexamide 
and actinomycin D. 6 Time point and inhibitor exper- 
iments were not performed on occlusive samples 
because of  specimen size limitations. 
Northern  analysis. Six specimens--2 aneu- 
rysms, 2 occlusive, and 2 normal--were analyzed. 
The average patient age was 75 +- 8 years for aneu- 
rysms, 55 --- 6 years for occlusive, and 40 + 13 years 
for normal aorta. The 2.5 kb uPA band was mea- 
sured on a bio-imager and normalized to the 
GAPDH signal, revealing 1.07 -+ 0.54 for aneu- 
rysms, 0.54 _+ 0.08 for occlusive, and 0.01 _+ 0.01 
for normal aorta. An ANOVA was performed which 
revealed a p = 0.1. Although the sample sizes were 
small, the averagc values for the three groups fol- 
lowed the same trend as the uPA protein levels in the 
supernatants, with aneurysmal specimens exhibiting 
the highest levels, followed by occlusive and then 
normal aorta. This suggests that the elevations of  
uPA may be controlled at the level of transcription. 
On the Northern blot (Fig. 2) there were no clear 
uPA bands on the lanes with RNA from normal 
tissue but strong GAPDH signals were present, sug- 
gesting that the amount of uPA in these specimens 
was below the level of detection for Northern analy- 
sis. A 1.1 kb tPA probe obtained from the American 
Type Culture Collection (#67587, Rockville, Md., 
U.S. patent #04766075) was also hybridized to this 
membrane, which was positive on the endothelial cell 
tissue culture lane but exhibited no clear bands on 
the tissue RNA lanes (data not shown). Perhaps a 
more sensitive method of quantitation, such as re- 
verse transcriptase polymerase chain reaction, would 
be more useful in detecting tPA mRNA levels in 
aortic tissue. 
DISCUSSION 
Understanding the regulation of fibrinolysis and 
tissue remodeling, two important functions of plas- 
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min, may provide future therapeutic methods for the 
treatment of atherosclerotic and aneurysmal disease. 
Evidence is accumulating to support asignificant role 
for uPA in ECM degradation and tissue remodeling. 
Migrating endothelial cells exhibit an increased uPA 
activity that decreases to background levels on cessa- 
tion of migration. 7 Activation of uPA on the cellular 
surface is localized by the uPA receptor. The receptor 
is rapidly polarized to the leading front of  migrating 
cells where it binds uPA, allowing localized activa- 
tion of plasminogen and degradation of the ECM. 8 
Various cancers, which can be thought of as unregu- 
lated forms of tissue remodeling, have been shown to 
exhibit an increased expression ofuPA. Ovarian can- 
cer cells in tissue culture have been shown to secrete 
17 to 38 times higher levels of uPA than normal 
ovarian cell lines, 9 and this elevated level of uPA has 
been associated with malignant transformation fthe 
ovarian surface epithelium. 1° Additionally, increases 
in uPA in breast cancer have been associated with a 
poor prognosis, n presumably as a result of  its inva- 
sire effect. 
Diseased aorta has been shown to contain inflam- 
matory cell infiltrates, with aneurysms exhibiting the 
largest amount followed by occlusive atherosclerotic 
aorta and a relative absence of inflammation i  nor- 
mal aorta. 12 In situ hybridization studies of AAA 
localized uPA mRNA to these infiltrates as well as to 
scattered inflammatory cells with a morphology re- 
sembling macrophages in the thickened intima and 
media. In contrast, normal aorta and areas of AAA 
devoid of inflammation were negative for uPA 
mRNA. ~3 Aneurysms are heterogeneous, with areas 
of arteriosclerosis exhibiting increased wall thickness 
and areas of  relative thinning, which presumably are 
the site of potential rupture. Many cell types, includ- 
ing endothelial cells, 14 vascular smooth muscle 
cells, as and macrophages, 16 synthesize uPA, and the 
expression of  uPA is regulated by various cytokines 
such as interleukin-1 and tumor necrosis factor-a, s 
In addition to tissue remodeling, plasmin plays an 
important role in fibrinolysis. Fibrin clots are de- 
graded by plasmin, resulting in dissolution ofthrom- 
bus and sometimes vessel recanalization. Plasmino- 
gen is normally incorporated into thrombus where it 
can be converted to plasmin by tPA, and fibrin must 
be present for the activation of  plasmin by tPA. s 
PAI-1 regulates this process by complexing with 
both tPA and uPA, thereby resulting in a loss of 
plasminogen activation potential. High plasma 
PAI-1 levels have been associated with thrombotic 
complications such as deep venous thrombosis ~7 and 
myocardial infarction is by promoting an overall de- 
crease of fibrinolytic activity. Peripheral arterial dis- 
ease has been associated with both elevated plasma 
tPA antigen levels and increased PAI-1 activity. The 
tPA antigen is increased because of the inactive tPA- 
PAI-1 complexes and results in an overall decrease in 
fibrinolytic activity. 19 
The blood vessel wall is the site of origin of 
plasma tPA. In AAA, tPA mRNA has been localized 
by in situ hybridization to macrophage-like c lls in 
the inflammatory infiltrate, and it has been shown 
within the lumenal endothelial cells in normal aor- 
ta. 13 111Indium labeled monoclonal antibodies 
against PA injected into patients before AAA repair 
demonstrated increased tPA accumulation i the an- 
eurysms on scintigrams. In this same study, tissue 
specimens collected at the time of Surgery exhibited 
tPA within the aneurysmal wall and the lumenal 
thrombus. 2° In vitro studies have shown that tPA 
stimulates vascular smooth muscle cell proliferation 2~ 
and migration, is
Using tissue explant supematants, we have dem- 
onstrated elevated levels of both plasminogen activa- 
tors in diseased aorta. In the present study, levels of 
tPA are threefold higher in diseased versus normal 
aorta. There was no significant difference between 
occlusive and aneurysmal specimens. In contrast o 
these findings, a previous report from Reilly et al. 4 
measuring tPA in diseased aorta found significant 
differences between all three aortic types, with aneu- 
rysms exhibiting the highest level, followed by nor- 
mal aortas and the lowest level in occlusive aortas. 
This study used protein extracts, and tPA levels were 
reported as ng of  antigen/mg of protein in the cx- 
tract. We also performed protein extract experiments 
but found no significant differences in tPA levels 
between the aortic types using this method 4,6 (data 
not shown). Technical difficulties arose from measur- 
ing total protein in the extracts. We used two differ- 
ent methods but observed variance within the same 
samples to be as high as 40%, and there were marked 
differences in total protein levels between the two 
methods. Dialyzing the extracts before measurement 
of  total protein did not improve the variance. We 
believed that total protein was not a consistent de- 
nominator for comparison of plasminogen activator 
levels and used the method of tissue explant superna- 
tants instead. 
In the current study, uPA was differentially ex- 
pressed using tissue explant supernatants in the three 
aortic types. Reilly et al. 4 were unable to quantitate 
uPA levels in their protein extract experiments. They 
diluted all of their samples to contain 1 mg/ml  of 
total protein before assay o fuPA levels, which prob- 
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ably led to concentrations of uPA that were below 
the level of detection in their immunoassay. They 
did, however, detect uPA activity in the extracts with 
fibrin autography, which is a more sensitive assay for 
detecting uPA. We did not standardize the protein 
levels in our protein extracts before assay and were 
able to detect uPA antigen, but found no statistically 
significant differences between the three aortic types 
(data not shown). Once again, difficulties with mea- 
suring total protein in the extracts led us to use the 
method of tissue explant supematants. 
To further characterize tissue explant superna- 
tants, we performed time course and inhibitor stud- 
ies. Levels of both plasminogen activators increased 
over time in the aneurysmal supernatants and in the 
uPA normal supernatants, but levels oftPA increased 
initially and then slightly decreased after 8 hours in 
the normal samples. Inhibition of protein and RNA 
synthesis by the addition of cyclohexamide and acti- 
nomycin D revealed no significant differences in ei- 
ther of the plasminogen activator levels, suggesting 
that the proteins were being released into the super- 
natants and not being actively synthesized. 
Protein levels of uPA were elevated, which led us 
to perform Northern analysis to quantitate mRNA 
levels. Although not statistically significant, the dif- 
ferences in the uPA transcripts followed the same 
trend as the protein data, with aneurysms expressing 
the highest levels, followed by occlusive aorta, and 
normal aorta exhibiting the lowest values. In fact, 
normal aorta revealed essentially no signal above 
background, suggesting that the level ofuPA expres- 
sion is below the level of detection for Northern 
analysis and that more sensitive methods, such as 
reverse transcriptase competitive polymerase chain 
reaction, should be used. Hybridization with tPA 
revealed message on the positive control lanes, but 
no signal above background levels on the aortic tis- 
sue lanes. Reilly et al. 4 also performed Northern 
analysis on aneurysmal, occlusive, and normal aorta. 
They obtained their normal specimens from autop- 
sies, and the RNA extracted from these specimens 
was degraded and did not allow comparison with 
diseased aorta. Comparison of uPA and tPA mRNA 
in aneurysmal nd occlusiv~e aorta revealed variability 
of plasminogen activator expression, but no signifi- 
cant differences. Similar to our study, sample num- 
bers were small (n = 2 for each group), making 
meaningful statistical analysis difficult. 
The differential expression ofuPA, with the high- 
est levels appearing in AAA, mal~e it an attractive 
molecule to explain the previously described eleva- 
tions of plasmin seen in aneurysms.1 Localization of  
uPA to the inflammatory infiltrate by in situ hybrid- 
ization 13 correlates with earlier observations of in- 
creased inflammation i  AAA as compared with oc- 
clusive aorta 12 and may be responsible for the 
differential expression of uPA observed in this study. 
Elevations of tPA were also observed in this study, 
but levels in aneurysmal nd occlusive disease were 
similar. Previous reports have described elevations of 
PAI-1 in diseased as compared with normal aorta, 
and this elevation was associated with the arterioscle- 
rosis present in both aneurysmal and occlusive dis- 
ease. 6,22 Possible explanations for this association of 
increased tPA with arteriosclerosis include thrombus 
in the diseased aortic wall, which may be responsible 
for releasing incorporated tPA. It has also been 
shown, in tissue culture models, that thrombin, 
which is incorporated into the thrombus, increases 
tPA release from vascular smooth muscle cells 23 and 
endothelial cells. 24 
A potential confounding factor in this study is the 
differences in the ages of  the three groups (normal, 
48 + 13 years; occlusive, 50 +_ 13 years; and AAA, 
66 -+ 10 years). Most of the previous work dealing 
with levels of tPA and age have been performed on 
serum samples, with the majority of the authors 
showing an age-related increase, 2s-29 whereas an- 
other report reveals an age-related decrease. 3°A lit- 
erature search failed to find any data regarding serum 
uPA levels and age. The current report studied levels 
of the plasminogen activators in the aortic wall, and 
no age-related differences were noted; however, the 
number of samples was small. The age of the normal 
and occlusive groups was very similar and yet here 
was a statistically significant difference between the 
tPA levels of  these two groups. On the other hand, 
no significant difference in the tPA levels of the oc- 
clusive and AAA groups was detected, even though 
the AAA group, on the average, was older than the 
occlusive group. We are not aware of any previous 
studies that compared arterial wall levels of the plas- 
minogen activators and age. Other researchers have 
studied tissue levels of the plasminogen system and 
found no correlation with age of tPA levels in breast 
cancer. 31 Increased levels of uPA, however, were 
associated with increased age in pulmonary adeno- 
carcinoma. 32 
Finally, antigen levels oftPA and uPA were mea- 
sured in the tissue explant supernatant s udies rather 
than the activity of  these proteins as a result of  the 
instability of these molecules in the tissue culture 
media. PAL1 is thought o be secreted in an active, 
unstable form with a half-life of 75 minutes at 
37 ° C 33 and in this system, is present in approxi- 
JOURNAL OF VASCULAR SURGERY 
Volume 25, Number 1 Shireman et al. 163 
mately 30-fold to 200-fold higher levels than the 
plasminogen activators. 6 Both uPA and tPA are se- 
creted in a proenzyme form that is activated by plas- 
min cleavage. Active uPA and t_PA in tissue culture 
media are rapidly inhibited by binding to the more 
abundant  PAI-134; therefore, there would be essen- 
tially no active components of the plasminogen sys- 
tem at the 48 hour time point chosen in this study. 
We conclude that tPA levels in atherosclerotic 
aorta are threefold higher than in normal specimens 
and that uPA is differentially expressed in aneurys- 
mal, occlusive, and normal aorta. As uPA plays an 
important role in tissue remodeling, our findings 
may also reflect the relative tissue repair activities in 
these three types of specimens and may explain the 
previously described elevations of plasmin observed 
in AAA. 1 
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